-
Mashup Score: 3SGLT2 Inhibitors in Patients With Cancer Therapy-Related Cardiotoxicity: An Unexpected Benefit?∗ - 4 month(s) ago
Corresponding Author
Source: www.jacc.orgCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 7
Diabetes, Obesity & Metabolism is an interdisciplinary journal for clinical & experimental pharmacology and therapeutics relating to metabolic & endocrine disease.
Categories: General Medicine News, CardiologistsTweet
-
Mashup Score: 23
For the podcast associated with this article, please visit https://academic.oup.com/eurheartj/pages/Podcasts.
Source: academic.oup.comCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 5
Sodium Glucose co-Transporter 2 (SGLT2) inhibitors (also known as ‘gliflozins’) represent a cornerstone to treat diabetes mellitus. Moreover, recent randomized clinical trials have demonstrated imp…
Source: www.tandfonline.comCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 3Treatment effect of canagliflozin for patients on therapy for heart failure: Pooled analysis of the CANVAS program and CREDENCE trial - 6 month(s) ago
Canagliflozin is a sodium–glucose cotransporter 2 inhibitor that has been shown to reduce cardiovascular events in diabetic patients with and without heart failure (HF). Whether the clinical benefits and safety profile of canagliflozin are different in those on a beta blocker and an angiotensin-converting enzyme inhibitor/angiotensin receptor blocker (BB + RAASi) is unknown.
Categories: General Medicine News, CardiologistsTweet
-
Mashup Score: 9Empagliflozin Suppresses the Differentiation/Maturation of Human Epicardial Preadipocytes and Improves Paracrine Secretome Profile: - 6 month(s) ago
Highlights • SGLT2 is primarily expressed in human preadipocytes in the epicardial adipose tissue. • The expression levels of SGLT2 diminish as the preadipocytes are differentiated to mature adipoc…
Source: www.jacc.orgCategories: Latest Headlines, Partners & KOLsTweet-
This #JACCBTS study demonstrated that the secretome profile modification of human EAT by #SGLT2i suppresses oxidative stress in human cardiomyocytes. Intervention in the quantity & quality of EAT may be a new therapeutic target for preventing #CVD. https://t.co/boCt3TdcXz #cvPrev https://t.co/TgL1oCtarT
-
-
Mashup Score: 1
OBJECTIVE. To evaluate the comparative cardiovascular effectiveness and safety of sodium–glucose cotransporter 2 inhibitors (SGLT-2is), glucagon-like peptide 1
Source: diabetesjournals.orgCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 2
This meta-analysis report that GLP1-RA and SGLT2i reduced with a similar efficacy not only MACE as MI, but also cardiovascular mortality and all-cause mortality at a median 3-year follow-up. SGLT2i were more protective in HFH and WRF than GLP1RA. These new data highlight the efficacy of SGLT2i not o …
Source: pubmed.ncbi.nlm.nih.govCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 4Mortality, Outcomes, Costs, and Use of Medicines Following a First Heart Failure Hospitalization: EVOLUTION HF - 7 month(s) ago
Abstract Background There are few contemporary data on outcomes, costs, and treatment following a hospitalization for heart failure (hHF) in epidemiologically representative cohorts. Objectives Thi…
Source: www.jacc.orgCategories: Latest Headlines, Partners & KOLsTweet
-
Mashup Score: 21SGLT2i Pocket Guide and Infographic - American College of Cardiology - 8 month(s) ago
SGLT2i Pocket Guide and Infographic
Source: www.acc.orgCategories: Cardiology News and Journals, Latest HeadlinesTweet
RT @JTThibs: Are #SGLT2i then cardioprotective? Editorial here: https://t.co/YbIUm1bo0X @OhadOrenMD @pnatarajanmd @DLBHATTMD